CureDuchenne Ventures Commits $500,000 to 4D Molecular Therapeutics to Advance Next-Generation AAV Delivery of Gene Therapy | DuchenneXchange

welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!
view full news & meetings section

CureDuchenne Ventures Commits $500,000 to 4D Molecular Therapeutics to Advance Next-Generation AAV Delivery of Gene Therapy


 CureDuchenne, a national venture philanthropy nonprofit focused on finding a cure for Duchenne muscular dystrophy (DMD), announced today a $500,000 investment into 4D Molecular Therapeutics (4DMT), a world-leader in Therapeutic Vector Evolution for adeno-associated virus (AAV) gene therapy vector discovery and product development, in an effort to advance gene therapy.

“Our investment into 4DMT will be the fourth investment by CureDuchenne Ventures, the investment arm of CureDuchenne, into gene therapy and gene editing. So far, we have had preclinical success in this area for Duchenne with our investments in duplication 2 exon skipping at Nationwide Children’s Hospital, Bamboo Therapeutics/Pfizer and Exonics Therapeutics, and we are very positive about the prospect of 4DMT’s work,” said Debra Miller, founder and CEO of CureDuchenne. “CureDuchenne’s investments are moving quickly through the drug development process and we look forward to safety and efficacy data for these potential therapies.”

https://www.duchennexchange.org/wp-content/uploads/2018/08/cd_rgb_300dpi-1.jpg

rareRelated